NY-ESO-1(157-170)

Investigational

Approval Year

Substance Class	Protein Created by `admin` on `Sat Dec 16 15:38:59 GMT 2023` Edited by `admin` on `Sat Dec 16 15:38:59 GMT 2023`
Protein Type	PEPTIDE
Protein Sub Type
Record UNII	OGZ705E0UN
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NY-ESO-1(157-170)

Common Name

English

SER-LEU-LEU-MET-TRP-ILE-THR-GLN-CYS-PHE-LEU-PRO-VAL-PHE

Systematic Name

English

L-PHENYLALANINE, L-SERYL-L-LEUCYL-L-LEUCYL-L-METHIONYL-L-TRYPTOPHYL-L-ISOLEUCYL-L-THREONYL-L-GLUTAMINYL-L-CYSTEINYL-L-PHENYLALANYL-L-LEUCYL-L-PROLYL-L-VALYL-

Systematic Name

English

NY-ESO-1 [WHO-DD]

Common Name

English

(2S)-2-(((2S)-2-(((2S)-1-((2S)-2-(((2S)-2-(((2R)-2-(((2S)-5-AMINO-2-(((2S)-2-(((2S,3S)-2-(((2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-AMINO-3-HYDROXY-PROPANOYL)AMINO)-4-METHYL-PENTANOYL)AMINO)-4-METHYL-PENTANOYL)AMINO)-4-METHYLSULFANYL-BUTANOYL)AMINO)-3-

Systematic Name

English

Classification Tree Code System Code

EU-Orphan Drug

EU/3/16/1634

Created by admin on Sat Dec 16 15:38:59 GMT 2023 , Edited by admin on Sat Dec 16 15:38:59 GMT 2023

Code System Code Type Description

PUBCHEM

146014907

Created by admin on Sat Dec 16 15:38:59 GMT 2023 , Edited by admin on Sat Dec 16 15:38:59 GMT 2023

PRIMARY

CAS

344422-47-5

Created by admin on Sat Dec 16 15:38:59 GMT 2023 , Edited by admin on Sat Dec 16 15:38:59 GMT 2023

PRIMARY

FDA UNII

OGZ705E0UN

Created by admin on Sat Dec 16 15:38:59 GMT 2023 , Edited by admin on Sat Dec 16 15:38:59 GMT 2023

PRIMARY

Related Record Type Details


					OGZ705E0UN

NY-ESO-1(157-170)

ACTIVE MOIETY

Comments:

The existence of overlapping CD8 and CD4 T-cell epitopes within certain tumor antigens provides an opportunity to test the hypothesis that relatively short peptides could be used to generate both CD8 and CD4 T cells against tumor. In this report, T-cell responses to a fragment of the tumor antigen NY-ESO-1 that contained an HLA-DP4-restricted helper T cell epitope as well as an HLA-A2-restricted cytotoxic T cell epitope were analyzed. One peptide, ESO:157170 (SLLMWITQCFLPVF) was recognized by both NY-ESO-1-reactive CD8 and CD4 T-cell clones. Both CD4 and CD8 T cells were efficiently generated from the peripheral blood of multiple melanoma patients after in vitro stimulations using ESO:157170. Dual-specific peptides containing both cytotoxic T-cell and helper T-cell epitopes may represent an attractive strategy of vaccine design aimed at generating tumor-reactive CD4 and CD8 T cells.


					OGZ705E0UN

NY-ESO-1(157-170)

ACTIVE MOIETY

Comments:

The most frequently detected response was toward the HLA-DP4-restricted NY-ESO-1(157-170) epitope, which is also recognized by effector T cells. Notably, functional Treg specific for an HLA-DR-restricted epitope within the NY-ESO-1(115-132) peptide were also identified at high frequency in tumor tissue, suggesting that NY-ESO-1-specific Treg may suppress local anti-tumor immune responses. Together, our data provide compelling evidence for the ability of a cancer vaccine to expand tumor antigen-specific Treg in the setting of advanced cancer, a finding which should be given serious consideration in the design of future cancer vaccine clinical trials.

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Molecular Formula	CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL